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ABSTRACT
Objective: To determine clinically meaningful changes (CMCs) for the
Functional Assessment of Cancer Therapy–Prostate (FACT–P).
Methods: We obtained data from a Phase III trial of atrasentan in meta-
static hormone-refractory prostate cancer patients (n = 809). We deter-
mined anchor-based differences using Karnofsky Performance Status
(KPS), bone alkaline phosphatase (BAP), hemoglobin, time to disease
progression (TTP), adverse events (AE), and survival. One-third and one-
half standard deviation and standard error of measurement (SEM) were
used as distribution-based criteria for CMCs. Comparison across baseline
FACT–P domains and derived scales [FACT–P total score, Trial Outcome
Index (TOI) score, prostate cancer subscale (PCS) score, pain-related
score, and FACT Advanced Prostate Symptom Index (FAPSI)] were con-
ducted for KPS, BAP, and hemoglobin using Student’s t tests. Twelve-week
change scores were compared for TTP, AE, and survival using ANCOVA.
Results: CMCs were estimated as 6 to 10 for FACT–P total score, 5 to 9
for FACT–P TOI score, 2 to 3 for FACT–P PCS, 1 to 2 for the 4 PCS
pain-related questions, and 2 to 3 for FAPSI. CMCs were also estimated
using distribution-based criteria. Kappa statistics were computed to deter-
mine the degree of correspondence between the recommended guideline of
1.0 SEM and empirically derived standards. Most of the kappas for
health-related quality of life domains and SEM standards had “substan-
tial” to “almost perfect” concordance.
Conclusions: The signiﬁcant relationship between clinical and quality of
life data provides support for the use of CMCs to increase interpretability
of FACT–P scores.
Keywords: clinically meaningful change, heath-related quality of life, mini-
mally important difference, prostate cancer.
Introduction
For patients faced with advanced illness and little hope for a cure,
the medical focus shifts from healing the patient to relieving
physical symptoms and maintaining function. This is especially
true for advanced prostate cancer, where patients are provided
with palliative rather than restorative interventions, and health-
related quality of life (HRQoL) assessment is critical in evaluation
of such treatments [1]. HRQoL measurements are routinely col-
lected in cancer clinical trials [2–4].
The US Food and Drug Administration recently released draft
guidance for inclusion of HRQoL data in product labels [5].
Patient-reported outcomes (PROs) measure patient health status
directly from the patient’s perspective and can be used to deter-
mine the effect of an intervention on one or more aspects of
patient health through assessment of simple (e.g., patient symp-
toms) to complex (e.g., HRQoL) concepts. To support the use of
PRO instruments in a clinical trial, researchers must provide
information on their reliability and validity, including their
ability to detect change. An important component of this is the
determination of the minimal important difference or MID [6].
Specifying an MID is a valuable benchmark for interpreting
clinical trial results.
One useful method to estimate an instrument’s MID entails
linking its score differences to meaningful cross-sectional differ-
ences and longitudinal change scores. Methods used for this
estimation have been classiﬁed as anchor-based (comparing score
differences or change with established external standards, termed
“anchors”). In contrast, distribution-based methods (evaluating
the dispersion of scores in the target population as an estimate of
the scale’s inherent variability) offer a likely range for the MID
[6].
In hormone-refractory prostate cancer (HRPC), performance
status, bone alkaline phosphatase (BAP), prostate-speciﬁc
antigen, hemoglobin, time to disease progression (TTP), and
pain-related adverse events (AE) can serve as potential anchors
[7,8]. Distribution-based measures rely on the statistical distri-
butions of HRQoL scores in a given study, such as standard
deviation (SD), standard error of measurement (SEM), or both
[9,10]. Distribution-based measures offer a way to identify clini-
cally meaningful changes (CMCs) and can corroborate clinical
anchor-based ﬁndings. These approaches have been used to
determine clinically meaningful differences in HRQoL scores
[10,11].
CMCs have been identiﬁed for several scales of the Func-
tional Assessment of Chronic Illness Therapy measurement
system, including lung cancer [4], fatigue [12], anemia [12],
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breast cancer [13], biological response modiﬁers [14], and col-
orectal cancer [15]. The purpose of this study is to establish CMC
ranges for the Functional Assessment of Cancer Therapy—
Prostate (FACT–P) using both anchor- and distribution-based
methods.
Patients and Methods
Study Population
In the M00-211 trial, 809 patients with metastatic HRPC were
randomly assigned to receive 10 mg of a novel endothelin-A
antagonist, atrasentan, or placebo. The primary objective was to
compare TTP between treatments. A tertiary objective was to
evaluate HRQoL. HRQoL was measured at baseline, week 4,
week 12, and every 12 weeks thereafter until week 72, or until
the patient experienced disease progression. The present research
is a secondary analysis to estimate a change in scores likely to be
clinically meaningful.
Quality of Life Instruments
The FACT–P is a validated questionnaire [16] used to assess
HRQoL in men with prostate cancer. FACT–P consists of
FACT–G (general), a 27-item self-report questionnaire that mea-
sures general HRQoL in cancer patients, and a 12-item prostate
cancer subscale (PCS). The PCS is designed speciﬁcally to
measure prostate cancer-speciﬁc quality of life. The FACT–P
Trial Outcome Index (TOI) is based on the physical and func-
tional well-being subscales of the FACT–G and the PCS. The
FACT–P total score includes the FACT–G and the PCS. The
FACT Advanced Prostate Symptom Index (FAPSI) includes eight
items from the FACT–P [17]. A higher overall score indicates
better HRQoL. The FACT–P total score, TOI, PCS score, PCS
pain-related score (four questions from the FACT–P interrogat-
ing pain speciﬁcally), and FAPSI were selected as the primary
focus of this analysis as they contain the most relevant questions
about symptoms and physical functioning.
Demographic and Clinical Data
Demographic information including age, ethnicity, and vital signs
were collected through the clinical trial procedures. Physician-
rated performance status was determined using the Karnofsky
Performance Status (KPS) scale. Clinical variables, including
BAP, and hemoglobin were also collected, and pain-related AE
were captured in the safety data set. TTP and survival time were
calculated.
The most useful clinical anchors are those that correlate at
least moderately with HRQoL scores [8,15]. The clinical anchors
used in this study were shown to have statistically signiﬁcant
relationships with HRQoL [18,19]. The relationship between
changes in HRQoL and TTP (early vs. late progressors), pain-
related AE, and survival time was investigated. Patients were not
asked to specify a level of change they considered important.
Statistical Analysis
Criterion-related validity was deﬁned as the relationship of test
scores to the meaningful anchors KPS score, BAP, and hemoglo-
bin. This information was used to assist in the interpretation of
scores based upon group differences. The associated FACT–P
total, TOI, FACT–P PCS, PCS pain-related score, and FAPSI
differences will likely establish an upper limit for a minimum
CMC in the score.
We used the minimum P-value approach [20] to determine
the appropriate cut-point for the clinical variables. In the
minimum P-value approach, selected values of the clinical vari-
ables are examined as candidates for the cut-points. The value is
chosen that best separates patient outcomes (i.e., survival)
according to maximum chi-square statistics and a minimum
P-value or a maximum relative risk. Cut-points were obtained
for each clinical variable using survival as an outcome, and
patients were divided into two groups around the cut-point.
Using independent samples Student’s t tests, we compared
baseline HRQoL scores among patients with different baseline
clinical characteristics: KPS, BAP, and hemoglobin. Effect sizes
were calculated using group-level means and then dividing by the
pooled within-group SD [21]. By convention, changes in the
range of 0.2 SD units represent a small change, 0.5 a moderate
change, and 0.8 a large change [21].
One-way analyses of covariance were used to determine the
sensitivity of the HRQoL domains to changes in clinical status,
such as TTP, pain-related AE, and survival. Baseline clinical
characteristics associated with the HRQoL domain scores were
included as covariates. The 12-week follow-up period was
selected for these analyses because it proved the optimal balance
between having sufﬁcient time to note signiﬁcant clinical change,
while minimizing missing data because of disease progression or
other reasons. Change scores were created by subtracting the
baseline HRQoL domain scores from the 12-week follow-up
scores. The change from baseline to week 12 in the HRQoL
domains was analyzed by response to treatment and changes to
clinical status. Effect sizes were calculated by dividing the mean
change scores by the SD of the baseline HRQoL score.
Finally, several methods were used to identify which magni-
tudes of change in HRQoL score would be considered clinically
meaningful. Empirically derived standards were compared with
several established distribution-based standards. Several compu-
tations were necessary to accomplish this. First, SD of baseline,
week 12, and change scores were computed and divided by 2 and
3 to establish one-half and one-third SD change standards. Next,
the SEM was computed: sx(1 - rxx)1/2, where sx = SD of the sub-
score and rxx = the reliability (internal consistency) of the scale.
On the basis of evidence offered by Wyrwich [10], patients were
classiﬁed on a one SEM standard as having “declined” (change
score fell by at least one SEM), “improved” (change score rose by
at least one SEM), or “no change” (change score was less than
one SEM). Next, patients were further classiﬁed into “declined,”
“improved,” or “no change” categories based on the empirically
derived standards. Cohen’s kappa statistic was used to determine
the degree of correspondence between the one SEM standard and
the empirically derived standard. These methods are based on
those used in similar studies estimating CMCs for the FACT
within other cancer types [4,13].
Results
Baseline Summary Statistics
Subjects (n = 809) ranged in age from 45 to 93 years
(mean = 71.8 years). Subject demographics and baseline clinical
variables are summarized in Table 1.
Baseline Differences in Clinical Indicators
Hemoglobin. The minimum P-value approach identiﬁed
11.6 g/dL as the optimal cut-point for hemoglobin (Table 1).
Patients with hemoglobin higher than 11.6 g/dL were found to
have higher FACT–P total score (P = 0.0002), TOI score
(P < 0.0001), PCS score (P = 0.0004), pain-related score
(P = 0.0006), and FAPSI score (P = 0.0002) than patients with
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hemoglobin lower than 11.6 g/dL. Patients with higher hemoglo-
bin had better HRQoL scores (Table 2).
BAP. Elevated BAP levels have been found to predict for poor
outcome in patients with HRPC [8,22,23]. The minimum P-value
approach identiﬁed 52.38 ng/ mL as the optimal cut-point for
BAP. Patients with baseline BAP higher than 52.38 ng/mL had
lower FACT–P total score, TOI score, PCS score, pain-related
score, and FAPSI score as compared with patients with BAP lower
than 52.38 ng/mL (P < 0.0001 for all scales). This suggests that
high BAP levels are associated with poor quality of life (Table 2).
KPS Scale. Baseline differences in FACT–P total score, TOI
score, PCS, pain-related score, and FAPSI by KPS score are
presented in Table 2. Those with a Karnofsky score of 100 had a
higher FACT–P total score, TOI score, PCS score, pain-related
score, and FAPSI score as compared with those with a Karnofsky
score less than 100 (P < 0.0001 for all scales). On these dimen-
sions, patients with higher Karnofsky scores reported better
HRQoL (Table 2).
Using the baseline variables as meaningful indicators of
patient status, we determined the upper limits for an MID. These
limits correspond to differences in FACT–P total, TOI, PCS,
pain-related, and FAPSI scores across the baseline variables that
represent effects of “small” to “moderate” (approximate range
of effect size = 0.20 to 0.60) size, per Cohen. Small to moderate
differences are considered minimal estimators of the MID,
similar to previous estimations of MID for lung [3] and breast
cancer [13]. The absolute differences in FACT–P total score
ranged from 7 to 10 (rounding to the nearest decimal). Similarly,
for the TOI, the difference ranged from six to nine. PCS score
differences ranged from two to three, PCS pain-related score
differences ranged from one to two, and FAPSI score differences
ranged from two to three.
Changes in HRQoL Over Time
Changes in HRQoL and TTP. The median TTP for the study
population was 87 days. A difference in HRQoL change scores
was observed between early progressors (EP) and later progres-
sors (LP), with EPs showing a greater decline than the LPs
(Table 3). The difference between these groups in FACT–P total
score change was 7.2. Differences between the EPs and LPs for
the TOI and PCS, and pain-related change scores were 5.9, 2.7,
and 1.7, respectively. The EPs and LPs differed on FAPSI by 2.0
(P < 0.0001 for all scales).
Changes in HRQoL and pain-related AE. A difference in the
HRQoL change scores was observed between patients experienc-
ing AE related to pain compared with those who did not, as
patients with pain AE showed a greater decline than those
without these events (Table 3). The difference between these
patient groups in FACT–P total score was 6.3. TOI, PCS,
and pain-related change scores differed between these groups by
6.1, 2.9, and 2.0. The two groups also differed on FAPSI by 2.2
(P < 0.0001 for all scales).
Changes in HRQoL and survival. The median survival time for
the patient population was 568 days. A difference in HRQoL
change scores was observed between patients with survival times
less than or equal to the median (short survival: SS) and those
Table 1 Baseline characteristics
Variable Variable
Age, years N = 809 Hemoglobin, g/dL N = 793
Mean (SE) 71.8 (0.29) Mean (SEa) 13.2 (0.045)
Median 72.0 Median 13.3
Range 45.0–93.0 Range 9.1–18.1
Race N = 809 BAP, ng/mL N = 769
Caucasian 770 (95%) Mean (SE) 59.1 (4.97)
Black 26 (3%) Median 25.2
Asian 8 (1%) Range 2.0–1903.8
Other 5 (1%) PSA, ng/mL N = 803
Weight, kg N = 807 Mean (SE) 215.1 (16.1)
Mean (SE) 84.5 (0.53) Median 72.9
Median 82.1 Range 1.7–5784.0
Range 47.0–176.9 Karnofsky score N = 809
Mean (SE) 93.8 (7.7)
Median 100
Range 60–100
BAP, bone alkaline phosphatase; PSA, prostate-speciﬁc antigen.
Karnofsky Performance Scale Index allows patients to be classiﬁed as to their functional
impairment.The lower the Karnofsky score, the worse the survival.
Table 2 Baseline differences in clinical indicators
Clinical indicator FACT–P total score FACT–P TOI score FACT–P PCS FACT–P PCS pain FAPSI
BAP, ng/mL (N)
>52.38 (192) 111.4 (19.3) 72.0 (15.1) 31.0 (6.7) 9.8 (3.9) 22.9 (5.4)
52.38 (577) 118.6 (17.2) 78.0 (13.2) 33.2 (6.6) 11.2 (3.8) 24.6 (4.9)
Mean difference -7.2 -6.0 -2.2 -1.4 -1.7
P-value <0.0001 <0.0001 <0.0001 <0.0001 <0.0001
Effect size 0.39 0.42 0.33 0.36 0.33
Hgb, g/dL (N)
>11.6 (709) 117.8 (17.4) 77.3 (13.5) 33.0 (6.5) 11.0 (3.8) 24.4 (5.0)
11.6 (84) 107.4 (22.2) 68.4 (17.6) 29.7 (7.7) 9.4 (4.3) 21.6 (6.1)
Mean difference 10.4 8.9 3.3 1.6 2.8
P-value 0.0002 <0.0001 0.0004 0.0006 0.0002
Effect size 0.52 0.57 0.46 0.39 0.50
Karnofsky (N)
Score = 100 (430) 121.3 (15.7) 80.4 (11.8) 34.2 (6.0) 11.7 (3.6) 25.4 (4.4)
Score < 100 (379) 111.1 (19.2) 71.7 (15.2) 30.8 (7.0) 9.8 (4.1) 22.6 (5.5)
Mean difference 10.2 8.7 3.4 1.9 2.8
P-value <0.0001 <0.0001 <0.0001 <0.0001 <0.0001
Effect size 0.58 0.64 0.52 0.49 0.56
FACT–P, Functional Assessment of Cancer Therapy—Prostate; TOI,Trial Outcome Index; PCS, prostate cancer subscale; FAPSI, FACT Advanced Prostate Symptom Index; BAP, bone alkaline
phosphatase; Hgb, Hemoglobin.
Karnofsky Performance Scale Index allows patients to be classiﬁed as to their functional impairment.The lower the Karnofsky score, the worse the survival.
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with survival times greater than median (long survival: LS), with
patients having SS showing a greater decline than those with LS
(Table 3). The difference in FACT–P total change score between
these groups was 5.9, while the differences were 5.4, 2.3, 1.4, and
1.5, respectively for the TOI, PCS, pain-related, and FAPSI mean
change scores (P < 0.0001 for all scales).
From these results, it was possible to estimate more precisely
CMCs on the ﬁve scales used (Table 4).
Comparisons with distribution-based criteria. The hypothesized
thresholds for meaningful change were then compared against
various distribution-based standards to determine an MID. To
specify more precisely a CMC on the HRQoL scales, we deter-
mined the correspondence between the empirically derived clini-
cal standards (above) and two established standards of a CMC.
The ﬁrst was one-third to one-half of an SD, which corresponds
to the magnitude Cohen suggests is representative of a small to
moderate effect size [22], and the second, one SEM, which has
been shown to be equivalent to a minimal clinically important
intra-individual change [9].
We ﬁrst calculated one-third and one-half SD for the baseline,
week 12, and change scores for the HRQoL domains (Table 5).
Baseline and week 12 SEMs were then calculated for all HRQoL
domains (Table 5). In comparison with the SD, the SEM is less
sample-dependent and accounts for the reliability of the scale
[24,25].
We determined the degree of concordance between the
hypothesized change standards and the one SEM standard to
verify which of our empirically derived, hypothesized standards
most closely approximated an MID. This was accomplished as
follows: First, we classiﬁed patients into “declined,”
“improved,” or “no change” using various point change stan-
dards for the different scales. 1) 6 to 10 points for the FACT–P
total score; 2) 5 to 9 points for the TOI; 3) 2 to 3 points for the
PCS; 4) 1 to 2 points for the pain-related score; and 5) 2 to 3
points for the FAPSI. To illustrate, for the 2-point standard for
PCS, patients were classiﬁed as “declined” if their change score
had fallen at least 2 points from baseline to week 12, “improved”
if it had risen at least 2 points, and “no change” if it fell between
-2 to +2. The same approach was used to classify patients into
“declined,” “improved,” or “no change” for the one SEM
standard.
Kappa statistics determining concordance between the
hypothesized change standards and the one SEM standards were
high. For the FACT–P PCS, baseline kappa values were 0.80,
0.98, 0.86, and 0.70 for the 2-, 3-, 4-, and 5-point standards.
Week 12 kappa values were 0.66, 0.84, 1.0, and 0.83 for the 2-,
3-,4-, and 5-point standards. Kappa statistics between 0.61 and
Table 3 Relationship between mean change from baseline to week 12 between health-related quality of life and clinical variables
Clinical indicator (N) FACT–P Total score FACT–P TOI score FACT–P PCS FACT–P PCS pain FAPSI
No. of items 39 26 12 4 7 or 8
TTP > median (362) -2.0 (14.6) -3.1 (11.6) -0.6 (6.0) -0.2 (3.7) -0.4 (4.4)
TTPmedian (447) -9.2 (16.0) -9.0 (13.0) -3.3 (6.4) -1.9 (4.0) -2.4 (4.8)
Difference 7.2 5.9 2.7 1.7 2.0
P-value <0.0001 <0.0001 <0.0001 <0.0001 <0.0001
Effect size 0.47 0.48 0.44 0.44 0.43
Pain-related AE (415) -8.4 (16.9) -8.8 (13.5) -3.2 (6.7) -2.0 (4.0) -2.4 (5.0)
No pain-related AE (394) -2.1 (13.5) -2.7 (10.7) -0.3 (5.5) 0.05 (3.5) -0.2 (4.1)
Difference -6.3 -6.1 -2.9 -2.0 -2.2
P-value <0.0001 <0.0001 <0.0001 <0.0001 <0.0001
Effect size 0.41 0.50 0.47 0.55 0.48
Survival time > median (268) -1.7 (12.3) -2.5 (9.0) -0.4 (4.9) -0.1 (3.1) -0.4 (3.6)
Survival timemedian (541) -7.6 (17.0)–1.7 (12.3) -7.9 (14.0)–2.5 (9.0) -2.7 (6.9)–0.4 (4.9) -1.5 (4.3)–0.1 (3.1) -1.9 (5.2)–0.4 (3.6)
Difference 5.9–7.6 (17.0) 5.4–7.9 (14.0) 2.3–2.7 (6.9) 1.4–1.5 (4.3) 1.5–1.9 (5.2)
P-value <0.00015.9 <0.00015.4 <0.00012.3 <0.00011.4 <0.00011.5
Effect size P Value <0.0001 <0.0001 <0.0001 <0.0001 <0.0001
Effect size 0.40 0.46 0.38 0.37 0.34
FACT–P, FunctionalAssessment of CancerTherapy—Prostate;TOI,Trial Outcome Index; PCS, prostate cancer subscale; FAPSI, FACTAdvanced Prostate Symptom Index;TTP, time to progression;
AE, adverse events.
Table 4 Minimally important difference ranges and effect sizes (anchor-
based analyses)
HRQoL domain
Range for clinically
distinguishable score
Effect size
range
FACT–P Total 6 to 10 0.39 to 0.58
FACT–P TOI 5 to 9 0.42 to 0.57
FACT–P PCS 2 to 3 0.33 to 0.52
FACT–P PCS pain 1 to 2 0.36 to 0.55
FAPSI 2 to 3 0.33 to 0.56
HRQoL, Health-related quality of life; FACT–P, Functional Assessment of Cancer
Therapy—Prostate; TOI, Trial Outcome Index; PCS, prostate cancer subscale; FAPSI, FACT
Advanced Prostate Symptom Index.
Table 5 Distribution-based criterion for clinical signiﬁcance
1/2 SD 1/3 SD SEM
FACT–P Total Score
Baseline 9.1 6.0 6.0
Week 12 10 6.9 6.9
Change from baseline to week 12 7.8 5.2
FACT–P TOI Score
Baseline 7.1 4.7 5.5
Week 12 8.2 5.4 6.3
Change from baseline to week 12 6.3 4.2
FACT–P PCS
Baseline 3.3 2.2 3.7
Week 12 3.7 2.5 4.1
Change from baseline to week 12 3.2 2.1
FACT–P PCS Pain
Baseline 2.0 1.3 2.3
Week 12 2.1 1.4 2.5
Change from baseline to week 12 2.0 1.3
FAPSI
Baseline 2.6 1.7 2.3
Week 12 2.9 1.9 2.6
Change from baseline to week 12 2.3 1.6
FACT–P, Functional Assessment of Cancer Therapy—Prostate; TOI, Trial Outcome Index;
PCS, Prostate Cancer subscale; FAPSI, FACT Advanced Prostate Symptom Index.
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0.80 are “substantial,” while those between 0.81 and 1.00 are
“almost perfect. [26]” Most of the kappa values for the HRQoL
domains and the SEM standards in this sample were “substan-
tial” to “almost perfect.”
Conclusions
We used a combination of anchor- and distribution-based
approaches to identify MIDs for FACT–P end points. Our rec-
ommended MID ranges are 6 to 10 for the FACT–P total score,
5 to 9 for the TOI, 2 to 3 for the PCS, 1 to 2 for the pain-related
score, and 2 to 3 for the FAPSI. These ﬁndings provide indirect
evidence for whole number estimates just above the lower bound
range values as the MIDs for these HRQoL domains. Because the
MID estimates determined here are based on one clinical trial in
advanced HRPC patients, future research should focus on veri-
fying these estimates in multiple patient populations, including
early-stage disease, to determine their broad applicability.
Effect size ranges for all four HRQoL domains were between
0.26 and 0.72, which is close to the small to moderate range
(0.20 to 0.60). Reporting a range as opposed to a single estimate
has been recommended because MIDs can vary across patients
and groups [9,27]. There is also recent evidence that the one SEM
rule of thumb may underestimate the MID for short-term
changes in more acute conditions [28]. When interpreting change
in response to a speciﬁc anchor, one should not expect all
domains to change.
On the basis of the rationale that patients who differ on
baseline clinical characteristics will also differ on HRQoL
domains, baseline indicators were used to determine likely upper
limits of the MID. We found that baseline differences on the
FACT–P domains in our sample support this notion, as those
with better clinical indicators also reported better quality of life.
Week 12 change scores were evaluated for the following
clinical indicators: TTP, pain-related AE, and survival. Patients
classiﬁed as EPs showed greater decline in HRQoL than late
progressors, while those with more pain-related AE displayed a
more notable decrease than those who did not experience such
AE.
Appropriate methods for interpreting changes in HRQoL
have not been developed at the same pace as the tools for assess-
ing HRQoL. With a wide range of HRQoL instruments involving
varying units of measurement, interpretation is challenging and
their meaning may not be evident to clinicians and researchers.
Identifying intraindividual change in HRQoL measures is critical
in the evaluation of the patient’s status. Better interpretation of
HRQoL results from clinical trials will enable clinicians to incor-
porate such information into their practices, including standards
of care.
For PRO end point data to be acknowledged as evidence of
treatment success, it is essential to document the instrument’s
psychometrics and MID. CMCs can help clinicians and research-
ers understand whether HRQoL differences between treatments
groups are important or whether changes over time in a group
are meaningful, such as when assessing responsiveness to
a treatment. One should be cautious when applying these criteria
in clinical practice. The MIDs should be used as guide to clini-
cians when more investigation may be warranted before making
therapeutic changes. MIDs can also be helpful as justiﬁcation for
sample size requirements necessary to determine clinical beneﬁt.
Our study is not without limitations. Because these estimates
are derived from a single trial, conﬁrmation in other popula-
tions is essential. Future research should also incorporate ques-
tions that would elucidate meaningful clinical change thresholds
for individual patients. These limitations notwithstanding, the
MIDs identiﬁed in this paper, in conjunction with traditional
clinical endpoints, contribute to the enhanced interpretation of
FACT–P scores. Clinicians and investigators can apply this
information to compare and evaluate treatment efﬁcacy in
patients with HRPC.
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